Cargando…

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells

Dendritic cells (DCs) can initiate and direct adaptive immune responses. This ability is exploitable in DC vaccination strategies, in which DCs are educated ex vivo to present tumor antigens and are administered into the patient with the aim to induce a tumor-specific immune response. DC vaccination...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bol, Kalijn F., Schreibelt, Gerty, Rabold, Katrin, Wculek, Stefanie K., Schwarze, Julia Katharina, Dzionek, Andrzej, Teijeira, Alvaro, Kandalaft, Lana E., Romero, Pedro, Coukos, George, Neyns, Bart, Sancho, David, Melero, Ignacio, de Vries, I. Jolanda M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471787/ https://www.ncbi.nlm.nih.gov/pubmed/30999964 http://dx.doi.org/10.1186/s40425-019-0580-6

Ejemplares similares

Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients
por: Bol, Kalijn, et al.
Publicado: (2015)

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy
por: Schreibelt, Gerty, et al.
Publicado: (2013)

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
por: van Willigen, Wouter W., et al.
Publicado: (2018)

Primary Human Blood Dendritic Cells for Cancer Immunotherapy—Tailoring the Immune Response by Dendritic Cell Maturation
por: Sittig, Simone P., et al.
Publicado: (2015)

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
por: Laureano, Raquel S, et al.
Publicado: (2022)

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
por: Boudewijns, Steve, et al.
Publicado: (2016)

Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets
por: Wimmers, Florian, et al.
Publicado: (2014)

Naturally circulating dendritic cells to vaccinate cancer patients
por: Bol, Kalijn F., et al.
Publicado: (2013)

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients
por: Boudewijns, Steve, et al.
Publicado: (2016)

Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen
por: Wculek, Stefanie K., et al.
Publicado: (2019)

Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination
por: van Willigen, Wouter W., et al.
Publicado: (2020)

Immunological responses to adjuvant vaccination with combined CD1c(+) myeloid and plasmacytoid dendritic cells in stage III melanoma patients
por: Bloemendal, Martine, et al.
Publicado: (2021)

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients
por: Bol, Kalijn F, et al.
Publicado: (2015)

Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets
por: Sköld, Annette E., et al.
Publicado: (2015)

A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets
por: Sittig, Simone P., et al.
Publicado: (2016)

Human Dendritic Cell Subset Isolation by Magnetic Bead Sorting: A Protocol to Efficiently Obtain Pure Populations
por: Flórez-Grau, Georgina, et al.
Publicado: (2023)

Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination
por: Aarntzen, Erik HJG, et al.
Publicado: (2013)

Metabolic Control of Dendritic Cell Functions: Digesting Information
por: Wculek, Stefanie K., et al.
Publicado: (2019)

Clinical translation section: accelerating the pace from bench to bedside
por: Kandalaft, Lana E, et al.
Publicado: (2011)

Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG
por: Wefers, Christina, et al.
Publicado: (2018)

Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy
por: Wimmers, Florian, et al.
Publicado: (2014)

A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013)

Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer
por: Bödder, Johanna, et al.
Publicado: (2021)

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2012)

Whole Tumor Antigen Vaccines: Where Are We?
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2015)

Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy
por: Mastelic-Gavillet, Beatris, et al.
Publicado: (2023)

High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
por: Westdorp, Harm, et al.
Publicado: (2020)

New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
por: Etxeberria, Iñaki, et al.
Publicado: (2020)

Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells
por: Sköld, Annette E., et al.
Publicado: (2018)

Initial Afferent Lymphatic Vessels Controlling Outbound Leukocyte Traffic from Skin to Lymph Nodes
por: Teijeira, Alvaro, et al.
Publicado: (2013)

Opportunities for immunotherapy in microsatellite instable colorectal cancer
por: Westdorp, Harm, et al.
Publicado: (2016)

Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2011)

PTEN Hamartoma Tumor Syndrome and Immune Dysregulation()()()
por: Eissing, Marc, et al.
Publicado: (2018)

Enterovirus-Infected β-Cells Induce Distinct Response Patterns in BDCA1(+) and BDCA3(+) Human Dendritic Cells
por: Schulte, Barbara M., et al.
Publicado: (2015)

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
por: Bol, Kalijn F., et al.
Publicado: (2016)

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients
por: Boudewijns, Steve, et al.
Publicado: (2016)

IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine
por: Mookerjee, Ananda, et al.
Publicado: (2019)

Human Dendritic Cell Subsets Undergo Distinct Metabolic Reprogramming for Immune Response
por: Basit, Farhan, et al.
Publicado: (2018)

T cell landscape within primary melanoma as a biomarker of survival after cancer vaccination in patients with metastatic disease
por: Vasaturo, Angela, et al.
Publicado: (2015)

Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3‐dioxygenase 1 with functional effects on T cell priming
por: Sittig, Simone P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_arg827hsjt243dagp2qgi5g2oa